Walter K. Kraft
Quick facts
Marketed products
- Doravirine (DOR) · Infectious Disease / Virology
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.
Phase 3 pipeline
- Rifapentine (RPT) · Infectious Disease
Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Walter K. Kraft
What are Walter K. Kraft's marketed drugs?
Top marketed products include Doravirine (DOR).
What is Walter K. Kraft's pipeline?
Walter K. Kraft has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Rifapentine (RPT).
Related
- Doravirine (DOR) · Infectious Disease / Virology
- Sector hub: All tracked pharma companies